Thesis overview

The COHR thesis turns on three axes:

1. NVDA-direct alignment via the $2B March 2 2026 common-stock investment — paired with NVDA’s parallel $2B Series A Convertible Preferred in Lumentum, structurally preserves the merchant InP EML duopoly. The question is durability: how does the relationship evolve as CPO becomes commercial, and how does NVDA-captive optics compress merchant-EML demand growth?
2. Vertically-integrated breadth vs. focus — Coherent’s stack spans InP devices, silicon photonics, transceiver assembly, ROADM/wave-shaper, SiC materials, and industrial fiber lasers. Breadth provides diversification but compresses operating leverage versus a more-focused competitor. The 2022 Coherent Inc. acquisition added scale but also debt; the 2026 NVDA injection materially de-risks the balance sheet.
3. 2028 CPO pivot optionality — like Lumentum, Coherent is positioned as a CPO source-laser supplier to NVIDIA Spectrum-X / Quantum-X. Vertical integration into transceivers gives Coherent more of the CPO value stack than Lumentum’s component-only path — but execution risk is meaningful (CPO timeline slip, NVDA in-sourcing, alternative photonic-integration paths winning).

Sub-pages

• Bull case — primary drivers and confirmation paths
• Bear case — primary risks and what would invalidate the bull thesis
• Risks — formal risk register (NVDA concentration, China trade restrictions, CPO timing, duopoly margin compression, balance-sheet leverage, SiC pricing pressure)
• Catalysts — dated near-term and long-term events
• Open questions — unresolved analytic items
• Cross-thesis implications — how COHR news affects LWLG, LITE, TSEM, GFS, MRVL theses